Posttranslational Modifications of RAS Proteins
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
genes encode four proteins that play central roles in oncogenesis by acting as binary molecular switches that regulate signaling pathways for growth and differentiation. Each is subject to a set of posttranslational modifications (PTMs) that modify their activity or are required for membrane targeting. The enzymes that catalyze the various PTMs are potential targets for anti-RAS drug discovery. The PTMs of RAS proteins are the focus of this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“Shokat and colleagues have exploited a shallow binding pocket under the Switch II region of RAS that is in proximity to the cysteine of G12C mutants (which account for 12% of RAS-driven tumors) and can be targeted with thiol-reactive compounds (Ostrem et al. 2013).”
BackgroundCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 1×
“Modern cancer genome analysis has confirmed that the three human RAS genes, KRAS, NRAS, andHRAS, are mutated in cancer more frequently than any other oncogene (Forbes et al. 2011; Prior et al. 2012).”
BackgroundA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“Modern cancer genome analysis has confirmed that the three human RAS genes, KRAS, NRAS, andHRAS, are mutated in cancer more frequently than any other oncogene (Forbes et al. 2011; Prior et al. 2012).”
BackgroundDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 2×
“Thus, the biochemical and cell biological properties of the products of RAS genes are a major focus for cancer biologists who hope to uncover vulnerabilities that can be exploited for drug discovery (Cox et al. 2014).”
BackgroundGEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903 · cited 1×
“Several proteins function as GEFs for RAS, including SOS, which transmits the signal from tyrosine kinase growth factor receptors to RAS (Bos et al. 2007).”
BackgroundThe Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · cited 1×
“Oncogenic mutations of RAS render it insensitive to GAP, allowing the GTPase to accumulate in the on state and sustain signaling (Trahey andMcCormick 1987; Scheffzek et al. 1997).”
BackgroundA Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211 · cited 1×
“Oncogenic mutations of RAS render it insensitive to GAP allowing the GTPase to accumulate in the on state and sustain signaling (13, 14).”
BackgroundTargeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Cárdenas, C., Miller, R. A., Smith, I., Bui, T., Molgó, J., Müller, M., Vais, H., Cheung, K.-H., Yang, J., Parker, I., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.007 · Cited by 1,026 · cited 1×
“A constant low level of calcium flux fromER stores tomitochondria is required formetabolic health and suppression of autophagy (White et al. 2005; Cárdenas et al. 2010).”
BackgroundRAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Differential Localization of Rho Gtpases in Live Cells
Michaelson, D., Silletti, J., Murphy, G., D'Eustachio, P., Rush, M., & Philips, M. R. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.1.111 · Cited by 679 · cited 1×
“Nevertheless, the bulk of endogenous RAC, RHO, and CDC42 are present in the aqueous environment of the cytosol (Michaelson et al. 2001).”
BackgroundSelf-citationWang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.01.013 · Cited by 632 · cited 2×
“Among these have been synthetic lethal screens that have yet to bear fruit (Downward 2015; Wang et al. 2017) and targeting the kinases downstream from RAS, an approach that has been very successful, although has yet to produce durable clinical responses (Samatar and Poulikakos 2014).”
BackgroundSmall molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
Ras signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594 · cited 2×
“Differential signaling outcomes of stringent, artificial targeting of activated RAS proteins to different cellular compartments supports this idea (Chiu et al. 2002) as does evidence for compartmentalized RAS signaling in Schizosaccharomyces pombe (Onken et al. 2006).”
BackgroundSelf-citationKinetics of interaction of nucleotides with nucleotide-free H-ras p21
John, J., Sohmen, R., Feuerstein, J., Linke, R., Wittinghofer, A., & Goody, R. S. (1990) · Biochemistry · doi:10.1021/bi00477a025 · Cited by 429
Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300
Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo
Ismail, S. A., Chen, Y.-X., Rusinova, A., Chandra, A., Bierbaum, M., Gremer, L., Triola, G., Waldmann, H., Bastiaens, P. I. H., & Wittinghofer, A. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.686 · Cited by 252
Schmick, M., Vartak, N., Papke, B., Kovacevic, M., Truxius, D. C., Rossmannek, L., & Bastiaens, P. I. H. (2014) · Cell · doi:10.1016/j.cell.2014.02.051 · Cited by 243 · cited 2×
“Bastiaens and colleagues have proposed that PDE6δ is absolutely required for proper trafficking of KRAS4B (Chandra et al. 2012; Schmick et al. 2014), a conclusion at odds with the fact that, whereas KRAS is essential for mouse development (Johnson et al.”
BackgroundLiang, X., Nazarian, A., Erdjument-Bromage, H., Bornmann, W., Tempst, P., & Resh, M. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104018200 · Cited by 227 · cited 4×
“The palmitate modification has long been known to promote association of both peripheral and intrinsic membrane proteins, such as HRAS and LAT respectively, to liquid ordered membrane domains in the past referred to as lipid rafts (97, 104, 105).”
BackgroundInfluentialK-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling
Wang, M.-T., Holderfield, M., Galeas, J., Delrosario, R., To, M. D., Balmain, A., & McCormick, F. (2015) · Cell · doi:10.1016/j.cell.2015.10.041 · Cited by 196
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergo, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418829 · Cited by 180
Switzer, C. H., Cheng, R. Y.-S., Ridnour, L. A., Glynn, S. A., Ambs, S., & Wink, D. A. (2012) · Breast Cancer Research · doi:10.1186/bcr3319 · Cited by 91 · cited 2×
“S-nitrosylation of RAS on cys118 has been shown to increase GDP/GTP exchange (Lander et al. 1995b; Williams et al. 2003) and has been implicated in breast cancer in which nitric oxide synthase 2 has been shown to be up-regulated (Switzer et al. 2012).”
BackgroundManu, K. A., Chai, T. F., Teh, J. T., Zhu, W. L., Casey, P. J., & Wang, M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0703 · Cited by 55 · cited 1×
“Importantly, Casey and Wang have recently established a requirement for ICMT in human tumor cell lines and showed that an ICMT inhibitor inhibits tumor growth and induces cancer cell death (Lau et al. 2014, 2017; Sun et al. 2016; Manu et al. 2017).”
Background
Cited by
KRAS4A directly regulates hexokinase 1
Amendola, C. R., Mahaffey, J. P., Parker, S. J., Ahearn, I. M., Chen, W.-C., Zhou, M., Court, H., Shi, J., Mendoza, S. L., Morten, M. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1832-9 · Cited by 203
Self-citationK-Ras prenylation as a potential anticancer target
Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62
Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology
László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., & Vas, V. (2021) · Cells · doi:10.3390/cells10030667 · Cited by 58
Ras sumoylation in cell signaling and transformation
Dai, W., Xie, S., Chen, C., & Choi, B. H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.033 · Cited by 27
Metadata
- Authors
- Ahearn, I., Zhou, M., & Philips, M. R.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2018-01-08
- Volume
- 8
- Issue
- 11
- Pages
- a031484
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2783231346
- Cited by
- 86
- References
- 28
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.